Teriflunomide is an immunomodulatory agent primarily used to treat multiple sclerosis by inhibiting dihydroorotate dehydrogenase (DHODH). Its effects include reducing recurrence rates and delaying disease progression, while paying attention to potential interactions with other drugs to ensure medication safety and effectiveness.

1. Effect of action

(1) Immune regulatory effect

Teriflunomide selectively inhibits DHODH, blocks pyrimidine synthesis, thereby inhibiting the proliferation of activated lymphocytes and reducing autoimmune reactions.

(2) Reduce recurrence rate

Clinical studies have shown that teriflunomide can significantly reduce the annual recurrence rate of multiple sclerosis patients and delay disease progression.

(3) Delaying disability progression

Long term use of Teriflunomide can slow down the accumulation of disability related to multiple sclerosis and improve the quality of life of patients.

2. Drug interactions

(1) CYP2C8 substrate

Teriflunomide is a potent inhibitor of CYP2C8, which may increase the blood drug concentration of CYP2C8 substrates such as regorazine. Dosage adjustment or avoidance of combination therapy is necessary.

(2) Warfarin

Teriflunomide may enhance the anticoagulant effect of warfarin, and close monitoring of INR values is necessary when used in combination to prevent an increased risk of bleeding.

(3) Oral contraceptive pills

Teriflunomide may reduce the effectiveness of oral contraceptives, and it is recommended to use additional contraceptive measures or switch to other contraceptive methods.

(4) Other immunosuppressive agents

The combination with leflunomide or other immunosuppressants may increase the risk of infection, and the pros and cons should be carefully evaluated.